Squamous Non-small Cell Lung Cancer Clinical Trial
Official title:
An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination With Gemcitabine and Cisplatin in the First-Line Treatment of Patients With Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)
The purpose of the Phase 1b portion of the study is to investigate how the body tolerates
necitumumab, in combination with gemcitabine and cisplatin chemotherapy as first line
treatment in participants with Stage IV squamous NSCLC and to determine the recommended dose
for the subsequent Phase 2 portion of the study.
The purpose of the Phase 2 portion of the study is to evaluate the efficacy of necitumumab in
combination with gemcitabine and cisplatin chemotherapy in participants with Stage IV
squamous NSCLC in a first-line setting.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03542461 -
Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)
|
Phase 3 | |
Not yet recruiting |
NCT04073537 -
Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT03717155 -
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
|
Phase 2 | |
Terminated |
NCT02204345 -
A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology
|
Phase 1/Phase 2 | |
Terminated |
NCT01911325 -
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
|
Phase 1 | |
Withdrawn |
NCT02924233 -
Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03319316 -
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
|
Phase 2 | |
Completed |
NCT04552535 -
A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
|
||
Not yet recruiting |
NCT05879484 -
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
|
Phase 1/Phase 2 | |
Completed |
NCT02367794 -
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
|
Phase 3 | |
Recruiting |
NCT04149691 -
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
|
Phase 1 | |
Recruiting |
NCT05243355 -
Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC
|
Phase 2 | |
Completed |
NCT03366480 -
A Study to Assess the Efficacy and Safety of ABTL0812
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04266730 -
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
|
Phase 1 | |
Terminated |
NCT02109016 -
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
|
Phase 2 | |
Completed |
NCT02106546 -
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
|
Phase 3 | |
No longer available |
NCT02475382 -
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen
|